| IRINOTECAN HYDROCHLORIDE | Small molecule | carcinoma | DNA topoisomerase I inhibitor | 4.0 | - | DailyMed |
| RUBITECAN | Small molecule | urethra cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Ewing sarcoma/peripheral primitive neuroectodermal tumor | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | glioblastoma multiforme | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| BELOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 3.0 | - | ATC |
| IRINOTECAN | Small molecule | head and neck malignant neoplasia | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Merkel cell skin cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | cancer | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| ETIRINOTECAN PEGOL | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | osteosarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| KARENITECIN | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | carcinoid tumor | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Splenic Marginal Zone Lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | brain cancer | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | cervical carcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | hypopharyngeal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Digestive System Carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | oral cavity mucoepidermoid carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | hepatocellular carcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | adenocarcinoma | DNA topoisomerase I inhibitor | 4.0 | - | DailyMed |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| ETIRINOTECAN PEGOL | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 3.0 | - | ATC |
| DS-1062 | Unknown | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | urethra cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| DS-1062 | Unknown | breast cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| 9-AMINOCAMPTOTHECIN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colonic neoplasm | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Digestive System Carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PATRITUMAB DERUXTECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 3.0 | Suspended | ClinicalTrials |
| PATRITUMAB DERUXTECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenosquamous carcinoma | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| 9-AMINOCAMPTOTHECIN | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | anaplastic oligodendroglioma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | follicular lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal neoplasm | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | primary peritoneal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| BELOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal neoplasm | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 0.5 | Completed | ClinicalTrials |
| BECATECARIN | Small molecule | small intestine cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | fallopian tube cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | appendix carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | urinary bladder carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | choroid plexus neoplasm | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | urinary bladder cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | breast neoplasm | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Mantle cell lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 0.5 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 1.0 | Enrolling by invitation | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | endometrial carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | chronic lymphocytic leukemia | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| BECATECARIN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | osteosarcoma | DNA topoisomerase I inhibitor | 2.0 | Suspended | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | triple-negative breast cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | gallbladder cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | mesenchymoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | lymphoblastic lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| RUBITECAN | Small molecule | ovarian cancer | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | laryngeal squamous cell carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| BECATECARIN | Small molecule | ovarian cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 0.5 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | medulloblastoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroendocrine carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | rhabdomyosarcoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | liver cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| DS-1062 | Unknown | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant epithelial tumor of ovary | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| EXATECAN | Small molecule | cervical cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | angioimmunoblastic T-cell lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | urinary bladder cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | urinary bladder cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| GIMATECAN | Small molecule | myelodysplastic syndrome | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Ovarian Germ Cell Tumor | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | biliary tract cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | grade II meningioma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| 9-AMINOCAMPTOTHECIN | Small molecule | lymphoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| ETIRINOTECAN PEGOL | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic neoplasm | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | liver cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | neoplasm | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | neoplasm | DNA topoisomerase I inhibitor | 4.0 | Enrolling by invitation | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Olfactory Neuroblastoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gliosarcoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroendocrine carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | kidney cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | biliary tract cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | brain neoplasm | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | metastasis | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | fallopian tube cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | small intestinal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | kidney cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | cancer | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| 9-AMINOCAMPTOTHECIN | Small molecule | ovarian cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | cerebral astrocytoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Hepatoblastoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | intrahepatic cholangiocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | verrucous carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | lethal midline granuloma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| 9-AMINOCAMPTOTHECIN | Small molecule | acute myeloid leukemia | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | anaplastic large cell lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| RUBITECAN | Small molecule | Central Nervous System Neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 4.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroendocrine carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gastroesophageal junction adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | carcinoid tumor | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | small intestine lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | kidney cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | oropharyngeal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| KARENITECIN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | oropharyngeal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | brain neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | renal cell carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| ETIRINOTECAN PEGOL | Small molecule | anaplastic oligodendroglioma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | central nervous system germ cell tumor | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | ovarian cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | lymphoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Burkitts lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | head and neck malignant neoplasia | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| ETIRINOTECAN PEGOL | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | glioblastoma multiforme | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| DIFLOMOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | colorectal neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastasis | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Hodgkins lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| GIMATECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | kidney cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | cervical cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | glioblastoma multiforme | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMATECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| DS-1062 | Unknown | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | gastric cancer | DNA topoisomerase I inhibitor | 1.0 | Suspended | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | cervical adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| BECATECARIN | Small molecule | male breast carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | lymphoblastic lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | inverted papilloma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | oral cavity mucoepidermoid carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | malignant glioma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Undifferentiated Pancreatic Carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic adenosquamous carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | Endometrial Serous Adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | neuroendocrine carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| EDOTECARIN | Small molecule | stomach neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | basal cell carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Ewing sarcoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic melanoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Olfactory Neuroblastoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | liver cancer | DNA topoisomerase I inhibitor | 4.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | adult T-cell leukemia/lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Mantle cell lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Hodgkins lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | triple-negative breast cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | optic pathway glioma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | neoplasm | DNA topoisomerase I inhibitor | 4.0 | - | ATC |
| DS-1062 | Unknown | breast cancer | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | anaplastic astrocytoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| DS-1062 | Unknown | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | triple-negative breast cancer | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal squamous cell carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | appendix carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| CAMPTOTHECIN-20-O-PROPIONATE | Small molecule | lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | neoplasm | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | urogenital neoplasm | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | gastric cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BECATECARIN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | penile cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| AR-67 | Small molecule | gliosarcoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | gastroesophageal junction adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| RUBITECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | glioma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal squamous cell carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| ETIRINOTECAN PEGOL | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | nodal marginal zone B-cell lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | rhabdomyosarcoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Undifferentiated Pancreatic Carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Ewing sarcoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | osteosarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| KARENITECIN | Small molecule | melanoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| RUBITECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | verrucous carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | brain glioma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| BELOTECAN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | nasal cavity and paranasal sinus squamous cell carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal neoplasm | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| BECATECARIN | Small molecule | lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | small intestine lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | anaplastic large cell lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | liver cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | gastroesophageal junction adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | rectal neoplasm | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | biliary tract cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | ovarian carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | cholangiocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| EXATECAN | Small molecule | Central Nervous System Neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | hepatocellular carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | glioblastoma multiforme | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| CAMPTOTHECIN-20-O-PROPIONATE | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 3.0 | Unknown status | ClinicalTrials |
| 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | rhabdomyosarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gallbladder cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| RUBITECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 3.0 | Unknown status | ClinicalTrials |
| RUBITECAN | Small molecule | peritoneum cancer | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | gallbladder cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | diffuse large B-cell lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | penile cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | ovarian cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| EXATECAN | Small molecule | prostate cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | prostate cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| EXATECAN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | medulloblastoma | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | lung neoplasm | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast neoplasm | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Malignant Bone Neoplasm | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| 9-AMINOCAMPTOTHECIN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant glioma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| ETIRINOTECAN PEGOL | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMATECAN | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | head and neck malignant neoplasia | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | gliosarcoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | brain cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| BECATECARIN | Small molecule | kidney cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | cerebral astrocytoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| KARENITECIN | Small molecule | melanoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | primary peritoneal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | cholangiocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Splenic Marginal Zone Lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | rectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | peripheral primitive neuroectodermal tumor | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | rectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | basal cell carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Pineoblastoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | embryonal rhabdomyosarcoma | DNA topoisomerase I inhibitor | 3.0 | Suspended | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| KARENITECIN | Small molecule | brain neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 3.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | cervical cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant tumor of extrahepatic bile duct | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | ganglioneuroblastoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | ovarian carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | gliosarcoma | DNA topoisomerase I inhibitor | 0.5 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | liver cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | central nervous system germ cell tumor | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gastrointestinal stromal tumor | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | peritoneum cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | cervical cancer | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| BECATECARIN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | neoplasm | DNA topoisomerase I inhibitor | 4.0 | - | ATC |
| IRINOTECAN | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | low grade glioma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | ganglioneuroblastoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | leukemia | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 4.0 | - | DailyMed |
| IRINOTECAN | Small molecule | colon mucinous adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | lymphoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | oligodendroglioma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | fallopian tube cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | choroid plexus neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant glioma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| TLC-388 | Small molecule | hepatocellular carcinoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Hepatoblastoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal squamous cell carcinoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| GIMATECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| EXATECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | laryngeal squamous cell carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| TLC-388 | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| EXATECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | urothelial carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | lethal midline granuloma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | glioblastoma multiforme | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | triple-negative breast cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | kidney Wilms tumor | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | glioblastoma multiforme | DNA topoisomerase I inhibitor | 0.5 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | anaplastic oligodendroglioma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | biliary tract cancer | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| DS-1062 | Unknown | breast cancer | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | rectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | central nervous system cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | squamous cell carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 0.5 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | rectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | nasal cavity and paranasal sinus squamous cell carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | rhabdomyosarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | liver cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | leukemia | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | triple-negative breast cancer | DNA topoisomerase I inhibitor | 4.0 | - | FDA |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gliosarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | breast carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | central nervous system cancer | DNA topoisomerase I inhibitor | 0.5 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | hepatocellular carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| BELOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast neoplasm | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | mycosis fungoides | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroendocrine carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| 9-AMINOCAMPTOTHECIN | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| KARENITECIN | Small molecule | ovarian cancer | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | mucinous carcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | angioimmunoblastic T-cell lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | mesothelioma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Merkel cell skin cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroendocrine carcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant glioma | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | embryonal rhabdomyosarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroendocrine carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | follicular lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| ETIRINOTECAN PEGOL | Small molecule | glioblastoma multiforme | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | metastatic melanoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| PATRITUMAB DERUXTECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 0.5 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 4.0 | Recruiting | ClinicalTrials |
| EXATECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 0.5 | Not yet recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | glioma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | malignant epithelial tumor of ovary | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | adult T-cell leukemia/lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | adenocarcinoma | DNA topoisomerase I inhibitor | 4.0 | - | DailyMed |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 4.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 4.0 | Unknown status | ClinicalTrials |
| IRINOTECAN SUCROSOFATE | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | non-Hodgkins lymphoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMATECAN | Small molecule | Central Nervous System Neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Ewing sarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | alveolar rhabdomyosarcoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | carcinoma | DNA topoisomerase I inhibitor | 4.0 | - | DailyMed |
| IRINOTECAN | Small molecule | anaplastic astrocytoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | anaplastic oligodendroglioma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | Ewing sarcoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | cervical carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colonic neoplasm | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 2.0 | Suspended | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant glioma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| PATRITUMAB DERUXTECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic endocrine carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | urethra cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | prostate cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| EDOTECARIN | Small molecule | glioblastoma multiforme | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | stomach neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| PATRITUMAB DERUXTECAN | Antibody | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | glioblastoma multiforme | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 0.5 | Recruiting | ClinicalTrials |
| BELOTECAN | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | leukemia | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | cervical cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant glioma | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BECATECARIN | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | endometrial carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | embryonal rhabdomyosarcoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 3.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal cancer | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| DS-1062 | Unknown | breast cancer | DNA topoisomerase I inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 0.5 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Central Nervous System Neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| EXATECAN | Small molecule | liver cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| CAMPTOTHECIN-20-O-PROPIONATE | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal neoplasm | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| RUBITECAN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Ewing sarcoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | gliosarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | kidney cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| RUBITECAN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| AR-67 | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | breast neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | angiosarcoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | peritoneum cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | optic pathway glioma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | malignant tumor of extrahepatic bile duct | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | central nervous system non-hodgkin lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN SUCROSOFATE | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 4.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastasis | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Lymphoma, AIDS-Related | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gliosarcoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| BELOTECAN | Small molecule | cervical cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| EXATECAN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | grade III meningioma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Burkitts lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | brain neoplasm | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| RUBITECAN | Small molecule | urinary bladder cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | grade III meningioma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | alveolar rhabdomyosarcoma | DNA topoisomerase I inhibitor | 3.0 | Suspended | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN SUCROSOFATE | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Ovarian Germ Cell Tumor | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | mesenchymoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| AR-67 | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Ewing sarcoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | MALT lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| AR-67 | Small molecule | myelodysplastic syndrome | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | hypopharyngeal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | head and neck malignant neoplasia | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 3.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | neutropenia | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | grade II meningioma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Unknown status | ClinicalTrials |
| RUBITECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| EXATECAN | Small molecule | peritoneum cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | rectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | esophageal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| EXATECAN | Small molecule | leukemia | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | biliary tract neoplasm | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| DS-1062 | Unknown | triple-negative breast cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Pineoblastoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Central Nervous System Neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colon adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | urinary bladder cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | cutaneous melanoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | metastasis | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Central Nervous System Neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | gastric adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | stomach neoplasm | DNA topoisomerase I inhibitor | 3.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic endocrine carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| BECATECARIN | Small molecule | biliary tract cancer | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 4.0 | - | DailyMed |
| BELOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PATRITUMAB DERUXTECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | biliary tract neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | head and neck malignant neoplasia | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | ovarian cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| RUBITECAN | Small molecule | ovarian cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | digestive system neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | small intestinal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | peritoneum cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| ETIRINOTECAN PEGOL | Small molecule | ovarian cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Ewing sarcoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | cutaneous melanoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | stomach neoplasm | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 4.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | biliary tract cancer | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | nodal marginal zone B-cell lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | endometrial carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 3.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | cerebellar astrocytoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | renal pelvis/ureter urothelial carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | diffuse large B-cell lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Sezary's disease | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| 9-AMINOCAMPTOTHECIN | Small molecule | ovarian neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | glioblastoma multiforme | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | leukemia | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| DS-1062 | Unknown | angiosarcoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | biliary tract cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | cerebellar astrocytoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Ewing sarcoma/peripheral primitive neuroectodermal tumor | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | ganglioneuroblastoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | urothelial carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | liver neoplasm | DNA topoisomerase I inhibitor | 4.0 | Withdrawn | ClinicalTrials |
| BECATECARIN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenosquamous carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN SUCROSOFATE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | urinary bladder cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Wilms tumor | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| TRASTUZUMAB DERUXTECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| GIMATECAN | Small molecule | malignant glioma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | chronic lymphocytic leukemia | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | MALT lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | alveolar rhabdomyosarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | stomach neoplasm | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | diffuse intrinsic pontine glioma | DNA topoisomerase I inhibitor | 0.5 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal neoplasm | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Central Nervous System Neoplasm | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 4.0 | Recruiting | ClinicalTrials |
| 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | embryonal rhabdomyosarcoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Sezary's disease | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | intrahepatic cholangiocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| EXATECAN | Small molecule | fallopian tube cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | prostate cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant glioma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | embryonal rhabdomyosarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | squamous cell carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | medulloblastoma | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | Digestive System Carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TLC-388 | Small molecule | renal cell carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | rhabdomyosarcoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Central Nervous System Neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| AR-67 | Small molecule | myelodysplastic syndrome | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| EXATECAN | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | glioblastoma multiforme | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | stomach neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | alveolar rhabdomyosarcoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gastric cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| EXATECAN | Small molecule | myelodysplastic syndrome | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Fallopian Tube Carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| RUBITECAN | Small molecule | cutaneous melanoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | triple-negative breast cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | diffuse intrinsic pontine glioma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | desmoplastic small round cell tumor | DNA topoisomerase I inhibitor | 0.5 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | mycosis fungoides | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic malignant neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| DS-1062 | Unknown | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal squamous cell carcinoma | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| ETIRINOTECAN PEGOL | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| TLC-388 | Small molecule | hepatocellular carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | digestive system neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Fallopian Tube Carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gastric carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | small intestine carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | salivary gland cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| RUBITECAN | Small molecule | endometrial cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | central nervous system non-hodgkin lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | embryonal rhabdomyosarcoma | DNA topoisomerase I inhibitor | 3.0 | Suspended | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | anus cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | gastrointestinal stromal tumor | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | rectal carcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | anaplastic astrocytoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | digestive system neuroendocrine neoplasm | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | brain neoplasm | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | renal pelvis/ureter urothelial carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant colon neoplasm | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| PATRITUMAB DERUXTECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal squamous cell carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | cervical cancer | DNA topoisomerase I inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN SUCROSOFATE | Small molecule | pancreatic carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal neoplasm | DNA topoisomerase I inhibitor | 4.0 | Completed | ClinicalTrials |
| KARENITECIN | Small molecule | Central Nervous System Neoplasm | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | Ewing sarcoma | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | neuroblastoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | renal cell carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | small intestine cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| EXATECAN | Small molecule | ovarian cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| SACITUZUMAB GOVITECAN | Antibody | triple-negative breast cancer | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | small intestine carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Hepatoblastoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN SUCROSOFATE | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gallbladder cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| EDOTECARIN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 3.0 | Unknown status | ClinicalTrials |
| EXATECAN | Small molecule | lymphoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| ETIRINOTECAN PEGOL | Small molecule | anaplastic astrocytoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| DS-1062 | Unknown | breast neoplasm | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| 9-AMINOCAMPTOTHECIN | Small molecule | peritoneum cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| BELOTECAN | Small molecule | ovarian cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | breast carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | medulloblastoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal squamous cell carcinoma | DNA topoisomerase I inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | salivary gland cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | hepatocellular carcinoma | DNA topoisomerase I inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | alveolar rhabdomyosarcoma | DNA topoisomerase I inhibitor | 3.0 | Suspended | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gastric adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| AFELETECAN | Small molecule | renal cell carcinoma | DNA topoisomerase I stabiliser | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | digestive system neuroendocrine tumor, grade 1/2 | DNA topoisomerase I inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | anus cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant glioma | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | glioblastoma multiforme | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal squamous cell carcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | inverted papilloma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | biliary tract cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| MURELETECAN | Unknown | neoplasm | DNA topoisomerase I inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IRINOTECAN | Small molecule | neoplasm | DNA topoisomerase I inhibitor | 4.0 | - | ATC |
| SACITUZUMAB GOVITECAN | Antibody | non-small cell lung carcinoma | DNA topoisomerase I inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| IRINOTECAN SUCROSOFATE | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | biliary tract cancer | DNA topoisomerase I inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| DS-1062 | Unknown | lung cancer | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | choroid plexus neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic ductal adenocarcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | endometrial carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 4.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal cancer | DNA topoisomerase I inhibitor | 1.0 | Terminated | ClinicalTrials |
| IRINOTECAN | Small molecule | lung cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | small cell lung carcinoma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | colorectal neoplasm | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | Central Nervous System Neoplasm | DNA topoisomerase I inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | Lymphoma, AIDS-Related | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | neutropenia | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| 9-AMINOCAMPTOTHECIN | Small molecule | kidney cancer | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| RUBITECAN | Small molecule | renal pelvis/ureter urothelial carcinoma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | oligodendroglioma | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | sarcoma | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | squamous cell carcinoma | DNA topoisomerase I inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | esophageal squamous cell carcinoma | DNA topoisomerase I inhibitor | 2.0 | Suspended | ClinicalTrials |
| IRINOTECAN | Small molecule | rectum cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | cancer | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | breast cancer | DNA topoisomerase I inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN | Small molecule | peripheral primitive neuroectodermal tumor | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | malignant glioma | DNA topoisomerase I inhibitor | 1.0 | Recruiting | ClinicalTrials |
| 9-AMINOCAMPTOTHECIN | Small molecule | acute lymphoblastic leukemia | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal neoplasm | DNA topoisomerase I inhibitor | 2.0 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | triple-negative breast cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | metastatic colorectal cancer | DNA topoisomerase I inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colorectal carcinoma | DNA topoisomerase I inhibitor | 2.0 | Terminated | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | small intestine cancer | DNA topoisomerase I inhibitor | 1.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | alveolar rhabdomyosarcoma | DNA topoisomerase I inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | colon mucinous adenocarcinoma | DNA topoisomerase I inhibitor | 3.0 | Completed | ClinicalTrials |
| IRINOTECAN | Small molecule | pancreatic adenocarcinoma | DNA topoisomerase I inhibitor | 0.5 | Completed | ClinicalTrials |
| IRINOTECAN HYDROCHLORIDE | Small molecule | gliosarcoma | DNA topoisomerase I inhibitor | 0.5 | Terminated | ClinicalTrials |